These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 23974779)

  • 1. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
    Gallagher EJ; LeRoith D
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):485-94. PubMed ID: 23974779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer.
    Ferguson RD; Gallagher EJ; Scheinman EJ; Damouni R; LeRoith D
    Vitam Horm; 2013; 93():51-98. PubMed ID: 23810003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
    McFarland MS; Cripps R
    Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients.
    Sciacca L; Vigneri R; Tumminia A; Frasca F; Squatrito S; Frittitta L; Vigneri P
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):808-15. PubMed ID: 23932729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
    Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
    Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes mellitus and the risk of cancer.
    Pandey A; Forte V; Abdallah M; Alickaj A; Mahmud S; Asad S; McFarlane SI
    Minerva Endocrinol; 2011 Sep; 36(3):187-209. PubMed ID: 22019750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetes, insulin, insulin analogues, and cancer].
    Müssig K; Staiger H; Kantartzis K; Fritsche A; Kanz L; Häring HU
    Dtsch Med Wochenschr; 2010 May; 135(18):924-9. PubMed ID: 20425680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal.
    Vora J; Ray K; Kosiborod M; Poulter NR; Rajagopalan S; Leiter LA
    J Diabetes Complications; 2017 Sep; 31(9):1451-1457. PubMed ID: 28655490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin: taking away the candy for cancer?
    Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
    Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes mellitus: influences on cancer risk.
    Szablewski L
    Diabetes Metab Res Rev; 2014 Oct; 30(7):543-53. PubMed ID: 25044584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes and cancer: a 2013 synopsis.
    Buysschaert M; Sadikot S
    Diabetes Metab Syndr; 2013; 7(4):247-50. PubMed ID: 24290094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glargine safety, diabetes and cancer.
    Rendell M; Akturk HK; Tella SH
    Expert Opin Drug Saf; 2013 Mar; 12(2):247-63. PubMed ID: 23394441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and cancer: licence to heal?
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Investig Drugs; 2010 Aug; 19(8):913-7. PubMed ID: 20557275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes and cancer: what is the connection?
    Cannata D; Fierz Y; Vijayakumar A; LeRoith D
    Mt Sinai J Med; 2010; 77(2):197-213. PubMed ID: 20309918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence.
    LeRoith D; Novosyadlyy R; Gallagher EJ; Lann D; Vijayakumar A; Yakar S
    Exp Clin Endocrinol Diabetes; 2008 Sep; 116 Suppl 1():S4-6. PubMed ID: 18777452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.